Infectious Disease
Moderna COVID-19 vaccine 93% effective, “permanent” after 6 months, the company says
August 05, 2021
Read for 1 minute
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
Moderna announced that its COVID-19 vaccine was 93% effective and that it was “sustained” for at least 6 months after the second dose was given.
The company also said it tested three booster candidates that showed “robust antibody responses to worrisome COVID-19 variants.”
Moderna said its COVID-19 vaccine was effective up to 6 months after the second dose was given.
Photo source: Adobe Stock
The data on the shelf life of the Moderna vaccine come from a final analysis of the Phase 3 COVE study, according to a press release. The company announced that it has begun the ongoing process of filing a biologics license application for its COVID-19 vaccine and expects to complete the process sometime this month.
With respect to Moderna’s booster candidates – the emergency-cleared mRNA-1273 and the investigational mRNA-1273.351 and mRNA-1273.211 – the company said that a Phase 2 study, in which a dose of 50 µg of each product was examined, showing strong reactions against the wild-type D614G COVID-19 strain and the gamma, beta and delta variants.
“The neutralization of the antibody levels after the boost approached that which was observed after the primary vaccination with two doses of 100 µg mRNA-1273,” said Moderna in the press release. “This data has been submitted to a peer-reviewed journal for publication.”
Moderna CEO Stéphane Bancel said in the press release that he was “pleased” with the results of the COVID-19 vaccine and that the company would remain “vigilant” about the Delta variant.
Several studies analyzing Moderna’s COVID-19 vaccine response in children and adolescents aged 6 months to 17 years as well as a “next generation” COVID-19 vaccine are ongoing, the company said.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
